Business Wire

Echodyne CEO Eben Frankenberg named “Businessman of the Year 2022” by Cutting-Edge Defense Technology Publication Battlespace

Share

Echodyne, the radar platform company, is pleased to announce Echodyne CEO Eben Frankenberg was voted “Businessman of the Year 2022” by the readers of Battlespace, an international publication dedicated to covering the most cutting-edge developments in the defense electronics industry. Frankenberg is set to receive the award at the Chepstow Military Race Day charity event, hosted by Battlespace; Soldiers, Sailors, Airmen and Families Association (SSAFA); and Chepstow Racecourse.

The event salutes both serving and former members of the United Kingdom’s armed forces and the unwavering commitment of those in veteran care. The award ceremony will be held in tandem with six competitive horse races, with sponsorship for each raising funds on behalf of three military charities – Combat Stress, The Royal Hospital Chelsea, and SSAFA.

Frankenberg accepts this award on the heels of a $135 million funding round in June to expand distribution, production, and development of its patented metamaterials electronically scanned array (MESA®) radar across the defense, security, and autonomous machine markets worldwide.

“I’m humbled to be chosen as ‘Businessman of the Year’ by Battlespace’s readership, made up of some of the most forward-thinking military electronic specialists, defense researchers, and defense industry professionals in the United Kingdom and beyond,” said Eben Frankenberg, CEO of Echodyne. “Since introducing our first radar in 2017, we’ve seen tremendous success with our proprietary metamaterials electronically scanned array technology both stateside and internationally. As we continue on our mission to be the world’s leading radar solutions company, our team couldn’t be more thankful to receive this recognition from such a key market and in front of an audience of the United Kingdom’s most dedicated countrymen and women.”

Those interested in attending the Chepstow Military Race Day event can purchase tickets here. Admission is free for anyone connected with the military – including serving and retired personnel, their family and friends.

About Echodyne

Echodyne, the radar platform company, designs and delivers high-performance compact, solid-state radars based on the company’s patented metamaterials ESA technology (MESA®). Ideally suited for defense, security, machine perception, and autonomy, Echodyne’s commercially priced electronically scanned array radars are used by defense and government agencies, autonomous systems developers, and security integrators for counter-UAS, border and perimeter security, critical infrastructure protection, unmanned aerial vehicles, and autonomous vehicles. Privately held, the company is based in Kirkland, Washington, and is backed by Bill Gates, NEA, Madrona Venture Group, Baillie Gifford, and Northrop Grumman among others. For more information, please visit: Echodyne.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

David Claxton, echodyne@wiseup.pr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

L&T Technology Services, PALFINGER Inaugurate GDC as Part of Multi-Year Engagement to Accelerate Product Development10.12.2025 09:30:00 EET | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced the inauguration of a state-of-the-art Global Development Center - APAC as part of a multi-year engagement with PALFINGER, an Austria-headquartered global pioneer in innovative crane and lifting solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209416315/en/ From PALFINGER, the ceremony was attended by Alexander Susanek (COO), Andreas Hille (Senior Vice President, Product Line Management and Engineering), Santhosh Rao (Senior Vice President Regional Sales & Service, Asia Pacific) and Arun C Bhongale (General Manager, SCM and Procurement). From LTTS, Mritunjay Singh (COO), Dr. Oliver Moron (Vice President, EU-DACH), Mohideen Farouk (Sales Director, EU-DACH), Jayant Joshi (Delivery Head, T&OH), Tejas B Shah (Delivery Head, Agriculture & Material Handling) and Sachin Nikam (Delivery Manager) we

New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 09:10:00 EET | Press release

Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where smart home and in-car connectivity adoption is among the highest globally, focused on four core themes: How consumers use audio across both home and in-car environments Their expect

Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 08:01:00 EET | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual

NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 06:00:00 EET | Press release

NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu

Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 04:50:00 EET | Press release

Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye